|
GB201800587D0
|
|
Bicycle peptide ligands specific for caix
|
|
GB201800593D0
|
|
Bicyclic peptide ligands specific for CD38
|
|
GB201800591D0
|
|
Bicycle peptide ligands specific for intergrin avb3
|
|
GB201800592D0
|
|
Bicycle peptide ligands specific for pd-l1
|
|
GB201721259D0
|
|
Bicyclic peptide ligands specific for EphA2
|
|
GB201715621D0
|
|
Bicycle peptide ligands specific for EphA2
|
|
GB201715239D0
|
|
Interaction with multiple sites
|
|
GB201713561D0
|
|
Peptide derivatives having novel linkage structures
|
|
GB201713560D0
|
|
Peptide ligands for binding to Mt1-Mmp
|
|
GB201713559D0
|
|
Modification of polypeptides
|
|
GB201712693D0
|
|
Bicyclic peptide ligands specific for nectin-4
|
|
GB201712589D0
|
|
Bicyclic peptide ligands specific for CD137
|
|
GB201712571D0
|
|
Bicyclic peptide ligands specific for PD-L1
|
|
GB201710406D0
|
|
Bicyclic peptide ligand drug conjugates
|
|
GB201708455D0
|
|
Ligands and methods of selecting binding targets for such
|
|
GB201707734D0
|
|
Bicyclic peptide ligands specific for EphA2
|
|
GB201706477D0
|
|
Modification of polypeptides
|
|
GB201705013D0
|
|
Bicycle peptide ligands specific for CD38
|
|
GB201701770D0
|
|
Bicyclic peptide ligands specific for integrin AVB3
|
|
GB201701834D0
|
|
Bicyclic peptide ligands specific for CD38
|
